Campbell Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Campbell Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-71,512	Closed	-$274K	–	45
2020 Q1	$274K	Sell	71,512 -300	-0.4%	-$1.39K	0.28%	28
2019 Q4	$434K	Sell	71,812 -38,639	-35%	-$264K	0.27%	44
2019 Q3	$835K	Buy	110,451 +12,662	+13%	+$143K	0.62%	33
2019 Q2	$1.32M	Sell	97,789 -82,998	-46%	-$958K	1.06%	26
2019 Q1	$980K	Buy	180,787 +9,100	+5%	+$44.3K	0.71%	31
2018 Q4	$510K	Buy	+171,687	New	+$940K	0.65%	26

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Campbell Capital Management's ZYNE Position: Q2 2020 in Review

Campbell Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 71,512 shares — an estimated $274K sold.

Campbell Capital Management first reported a position in ZYNE in Q4 2018 and held it in 6 quarters. The position peaked at $1.32M in Q2 2019. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

Campbell Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
Campbell Capital Management sold 71,512 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $274K.
Campbell Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and held it in 6 quarters.
Campbell Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $1.32M in Q2 2019.
74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Campbell Capital Management's 13F filing for Q2 2020, filed 8 Jul 2020.